PureTech Health PLC · LSE:PRTC

PureTech Health — Investor Presentation (September 2020)

71 slides from PureTech Health's investor presentation, September 2020

  1. Slide 1: PureTech: Developing BIG Medicines

    PURETECH Developing BIG Medicines BRAIN GUT

  2. Slide 2: Important information

    Important information The following presentation, including any printed or electronic copy of document may be forward-looking statements, including statements that By attending any delivery of, or electronically accessing, the these slides, the talks given by the presenters, the information relate t

  3. Slide 3: PureTech team has track record of outperforming

    PureTech team has track record of outperforming Daphne Zohar Bharatt Chowrira, PhD, JD Eric Elenko, PhD Founder & Chief Executive Officer President & Chief of Business & Strategy Co-founder & Chief Innovation Officer Built team, scientific network & pipeline; Recognized as a top leader in Former COO

  4. Slide 4: World class board of directors and R&D committee

    World class board of directors and R&D committee Christopher Viehbacher Raju Kucherlapati, PhD John LaMattina, PhD Robert Langer, ScD Board Chairman Board and R&D Committee Board and R&D Committee Board and R&D Committee Former CEO & Board Member at Sanofi, Harvard, Co-Founder of Millennium (acq. by

  5. Slide 5: Track record of outpacing industry averages

    Track record of outpacing industry averages PureTech has demonstrated high probabilities of clinical success; Particularly notable in the stages where industry failures are typically high 24 products and 0% 20% 40% 60% 80% 100% product candidates 83% Phase 1 Success 63% of which: 75% 13 are clinical

  6. Slide 6: A unique collaborative research & development model for advancing new medicines

    A unique collaborative research & development model for advancing new medicines Disease focused drug discovery based on proprietary insights and collaboration with the world’s leading experts on Brain, Immune, Gut The Brain-Immune-Gut (BIG) Axis: ~70% of immune cells and 500M neurons converge in the

  7. Slide 7: Existing value & near-term upside

    Existing value & near-term upside Founded Entities1 Wholly Owned Pipeline OUR PROGRAMS Discovery Preclinical Phase 1 Phase 2 Phase 3 LYT-100 Lymphatic flow disorders, incl. Readout from Phase 1b MAD study & Deupirfenidone lymphedema Initiation of POC study in 2020 LYT-100 Serious COVID-19 post-recov

  8. Slide 8: Karuna (PRTC Ownership: 12.8% plus royalties)

    Karuna (PRTC Ownership: 12.8% plus royalties*) Selectively activating muscarinic acetylcholine receptors in the brain Innovation Validation Value Realization living with Built top team of CNS experts led by former Nasdaq IPO, Phase 2 data ~2.7M schizophrenia in the US Lilly executive Steven Paul, MD

  9. Slide 9: PureTech's successes have outpaced market capitalization

    PureTech’s successes have outpaced market capitalization… Relative Value of Liquid Assets to PureTech (PRTC) Market Cap Value Components of Other Assets ($M) Akili (MDD cognitive FDA clearance & CE Mark for EndeavorRxTM Founded Entities1 Key PRTC impairment) and CE Mark for Plenity® 1,400 milestones

  10. Slide 10: With multiple near-term value drivers expected

    …With multiple near-term value drivers expected Product PureTech Candidate Ownership* 2020 2021 2022 LYT-100 100% Results from Phase 1b MAD & initiation of POC study in lymphedema Results from POC study in patients with breast cancer related lymph LYT-100 100% Initiation of serious respiratory compl

  11. Slide 11: Wholly Owned Pipeline with multiple near-term catalysts

    Wholly Owned Pipeline with multiple near-term catalysts PureTech’s brings its successful track record with Founded Entities to build Wholly Owned Pipeline Harnessing the lymphatic system & other immunological mechanisms Overview of Wholly Owned Pipeline OUR PROGRAMS Discovery Preclinical Phase 1 Pha

  12. Slide 12: LYT-100 designed to overcome challenges associated with pirfenidone

    LYT-100 (deupirfenidone) is designed to overcome significant challenges associated with pirfenidone, a successful anti-inflammatory and anti-fibrotic drug LYT-100 discovery process Patients discontinue current standard of care for idiopathic pulmonary fibrosis (IPF) due to dose-limiting toxicity (DL

  13. Slide 13: LYT-100 efficacy and tolerability advantages with pirfenidone's de-risked profile

    LYT-100 potentially has efficacy & tolerability advantages together with pirfenidone’s de-risked clinical profile Pirfenidone LYT-100 | Deupirfenidone – new chemical entity Short half-life and metabolic profile create limitations including: Differentiated PK profile provides potential advantages inc

  14. Slide 14: LYT-100 potential to address inflammatory and fibrotic conditions

    LYT-100 has potential to address a range of inflammatory and fibrotic conditions Pulmonary complications Lymphatic system diseases Other fibrotic & inflammatory disorders ~130k ~1M >4K in the United States in the United States in the United States with IPF or uILD overall with lymphedema are diagnos

  15. Slide 15: LYT-100 development plan overview

    LYT-100 development plan overview  Completed 2020: Initiated Phase 1 MAD study 2020: Expected POC initiation in lymphedema  Acute toxicity Multiple ascending dose and food-effect Patient proof-of-concept and biomarker study in breast study in healthy volunteers cancer-related, upper limb secondary

  16. Slide 16: LYT-200: Targeting galectin-9, a fundamental immunosuppressor in cancer

    LYT-200: Targeting galectin-9, a fundamental immunosuppressor in cancer Foundational biology: Mechanism of action:  Galectin-9 modulates multiple pathways of cancer immunosuppression disabling immune mediated cancer attack  LYT-200 has potential single agent efficacy, as well as combination CD tre

  17. Slide 17: LYT-200: Multiple lines of preclinical data supporting therapeutic potential

    LYT-200: Multiple lines of preclinical data supporting therapeutic potential Note: For patient-derived organoids, n = 20 tumor samples; Success defined as: >20% upregulation of at least two out of three T cell activation markers; success achieved in 60% of tumors with majority showing >2 fold activa

  18. Slide 18: LYT-200: Planned Phase I study design in metastatic solid tumors

    LYT-200: Planned Phase I study design in patients with metastatic solid tumors Dose escalation and dose expansion study Clinical Investigators ** 2nd Clinical Advisory Board held at ASCO 2019 Dose Finding (CRM) (all comers), Safety, Tolerability, RP2D, PK/PD, exploratory Filip Janku Osama Rahma Safe

  19. Slide 19: PureTech has a successful model for bringing breakthrough medicines to patients

    PureTech has a successful model for bringing breakthrough medicines to patients… Boundless Unbiased Scientific Value INNOVATION VALIDATION REALIZATION Collaborate with world’s Rigorous and disciplined Develop internally, partner, leading domain experts approach to develop, de- or advance through on

  20. Slide 20: Which has delivered innovative products and notable returns

    …Which has delivered innovative products and notable returns… 32X 46% IRR ROI from Karuna (KRTX) (2009 to present) Founded Entities (2010 to present)1 Since July 2018, PureTech and its Founded Entities have delivered: 8 Multiple 11 publications strategic clinical stage trial partnerships initiations

  21. Slide 21: With a history of execution & validation since IPO

    …With a history of execution & validation since IPO MAY 2015 DEC 2016 SEP 2017 PureTech London Successful Karuna Successful Gelesis pivotal IPO proof-of-concept study study for weight loss DEC 2019 JAN 2020 JAN – MAY 2020 Gelesis commercial Successful Akili study PureTech generated DEC 2017 partners

  22. Slide 22: Gelesis (PRTC Ownership: 21.0% plus royalties)

    Gelesis (PRTC Ownership: 21.0% plus royalties*) FDA cleared for the broadest patient population of any weight management product Innovation Validation Value Realization individuals in the US with Proprietary approach to potentially alter the FDA Clearance & European CE Mark ~150M overweight and obes

  23. Slide 23: Akili (PRTC Ownership: 34.0%)

    Akili (PRTC Ownership: 34.0%*) First game-based digital therapeutic cleared by the FDA for ADHD Innovation Validation Value Realization pediatric ADHD patients in Helped build top development and FDA Clearance & European CE Mark ~6.4M the US commercial team and raise funds  FDA cleared and granted

  24. Slide 24: Vedanta (PRTC Ownership: 50.4%)

    Vedanta (PRTC Ownership: 50.4%*) Developing a new class of drugs to modulate the human microbiome Upcoming Milestones and Value Innovation Validation Realization Rationally-defined consortia of gut bacteria; manufactured from pure  Four clinical-stage cell banks to produce drug product of known bac

  25. Slide 25: Follica (PRTC Ownership: 78.3% plus royalties)

    Follica (PRTC Ownership: 78.3% plus royalties*) Growing new hair based on innovative findings in regenerative biology Upcoming Milestones and Value Innovation Validation Realization  Proprietary in-office ~60K ~90M Follica is the first company to demonstrate new hair growth treatment to grow new ha

  26. Slide 26: Vor (PRTC Ownership: 11.8%)

    Vor (PRTC Ownership: 11.8%*) Selectively protecting healthy cells from targeted cancer therapies Upcoming Milestones and Value Innovation Validation Realization >20K acute myeloid leukemia  Ex vivo and mouse proof-of-concept ~60K patients in the US studies led by Siddhartha Mukherjee, MD, PhD; Also

  27. Slide 27: LSE Main Market / FTSE-indexed: PRTC

    LSE Main Market / FTSE-indexed: PRTC Headquartered in Seaport, Boston Market capitalization $1.06B (£792.67M) ~29% Board & Management as of August 31, 2020; 1.34 USD:GBP ~61% Disclosed Shareholders ~10% Analyst Coverage Other Shareholders 285,647,414 outstanding shares as of July 31, 2020 Jefferies

  28. Slide 28: PureTech: Developing BIG Medicines Q&A

    PURETECH Developing BIG Medicines Q&A

  29. Slide 29: Appendix A: Wholly Owned Pipeline

    Appendix A: Wholly Owned Pipeline 29

  30. Slide 30: Lymphedema: A chronic progressive disease with no FDA approved therapies

    Lymphedema: A chronic progressive disease with no FDA approved therapies ~1M individuals in the US A progressive disease with disability, disfigurement, and have lymphedema risks of serious comorbidities1 including ~500K breast cancer survivors with secondary lymphedema Current treatment options inc

  31. Slide 31: Injury to the lymphatics blocks fluid flow and creates inflammation and fibrosis

    Injury to the lymphatics blocks fluid flow and creates inflammation and fibrosis HEALTHY ARM LYMPHEDEMATOUS ARM Surgery and radiation damage Normal lymphatics drain Damaged lymphatics lymphatics fluid from tissue create blocked flow Fluid pumped from arm Fluid accumulates, causing Healthy arm throug

  32. Slide 32: Lymphedema: A feedback loop between inflammation and fibrosis

    Lymphedema: A feedback loop between inflammation and fibrosis A healthy lymphatic system Damaged lymphatics drains interstitial fluid fail to drain Immune cell infiltration in Fibrosis in arm tissue impairs arm promotes fibrosis2 flow and blocks regeneration3 Control Lymphedema Healthy lymphatics ma

  33. Slide 33: Preclinical model mimics human pathophysiology and tissue changes

    Preclinical model mimics human pathophysiology and tissue changes A healthy lymphatic system Damaged lymphatics drains interstitial fluid fail to drain Mouse tail lymphatics Lymphatic damage blocks flow1 40 p<0.01 CD45+ cells (%) 30 Immune cell infiltration 20 in affected tissue2 10 Lymphedematous C

  34. Slide 34: LYT-100: Once-daily treatment reduced swelling in preclinical models

    LYT-100: Once-daily treatment reduced swelling in preclinical models Mouse lymphedema model: ablation 120 Treatment Control begins Change in tail volume, % of tail lymphatics results in chronic 100 LYT-100 tail swelling, inflammation, and fibrosis 80 60 LYT-100 control 40 2 wks 4 wks WT WT 20 0 Tail

  35. Slide 35: LYT-100: Designed to address underlying mechanisms of lymphedema

    LYT-100: Designed to address underlying mechanisms of lymphedema Preclinical plasma concentrations of TNFα with LYT-100 In vitro reduction of TGF-β induced soluble collagen versus control production (mouse fibroblasts) LYT-100 reduced TGF-β induced fibrosis 36% reduction 35

  36. Slide 36: Respiratory complications of COVID-19

    Respiratory complications of COVID-19 Serious post-acute respiratory complications are an emerging issue for those who survive  Recent publications suggest a high proportion of mild, moderate and severe COVID-19 patients show signs of lung fibrosis at three weeks post symptom onset  In SARS, patie

  37. Slide 37: LYT-100: Serious respiratory complications following resolution of COVID-19

    LYT-100: Serious respiratory complications following resolution of COVID-19 Rationale Trial Design Multimodal mechanism of action LYT-100 showed anti-fibrotic and anti- Global, randomized, placebo-controlled trial inflammatory activity will evaluate LYT-100 in non-critical COVID-19 patients with res

  38. Slide 38: LYT-100: Focal segmental glomerulosclerosis (FSGS)

    LYT-100: Focal segmental glomerulosclerosis (FSGS) Segmental lesion in FSGS  Rare, progressive fibrotic  No specific treatments  Clinical proof of concept with  LYT-100 has favorable PK kidney disease that can designed to reduce fibrosis pirfenidone in FSGS demonstrated over pirfenidone which le

  39. Slide 39: LYT-210: Monoclonal antibody aimed at immunosuppressive γδ1 T cells

    LYT-210: Monoclonal antibody aimed at immunosuppressive γδ1 T cells Immunosuppressive γδ1 T cells TUMOR PROGRESSION Solid tumors harbor immunosuppressive γδ1 T cells that correlate with tumor aggressiveness / lower rate survival Works through multiple pathways to cause immunosuppression in the tumor

  40. Slide 40: LYT-210: Multiple lines of preclinical data supporting therapeutic potential

    LYT-210: Multiple lines of preclinical data supporting therapeutic potential Single agent activity in KPC LYT-210 candidate clone has excellent T cell activation with an anti-δ1 mAb in (pancreatic cancer) model drug properties: patient-derived organoid model (Published in Cell)  High affinity and s

  41. Slide 41: LYT-300: Oral allopregnanolone for a range of neurological disorders

    LYT-300: Oral allopregnanolone for a range of neurological disorders Despite FDA approval, 60-hr IV infusion has greatly limited Zulresso usage IV (60 hr infusion) Oral administration can enable usage across a range of neurological conditions Rationale Allopregnanolone  Dog/NHP pilot PK studies sho

  42. Slide 42: Additional programs in Wholly Owned Pipeline

    Additional programs in Wholly Owned Pipeline Three discovery programs designed to harness the lymphatic system Platform Application/Focus  Utilizes natural lipid transport mechanisms in order to potentially enable Glyph direct delivery of drugs into the lymphatic system and therefore enable or Tech

  43. Slide 43: PureTech well-positioned to unleash the potential of oral biotherapeutics

    PureTech is well-positioned to unleash the potential of oral biotherapeutics Limitations of protein-based therapeutics Advantages of the OrasomeTM technology platform: – Intravenous or subcutaneous administration – infusion reactions, barrier for repeat dosing – Lengthy scale-up timeline + Orally ad

  44. Slide 44: Glyph Technology Platform: Harnessing natural lipid-trafficking pathways

    Glyph Technology Platform: Harnessing the natural lipid-trafficking pathways to transport drugs via the lymphatics Traditional Small Molecules Lymphatic Trafficking Prodrugs Subject to first-pass metabolism Bypasses first-pass metabolism 44

  45. Slide 45: Glyph Technology Platform: Designed to utilize natural lipid transport system

    Glyph Technology Platform: Designed to utilize natural lipid transport system to enable lymphatic targeting Lipid prodrugs provide multiple opportunities to enhance small molecule drugs A A Transport to mesenteric lymph nodes B Enable oral route via B first-pass bypass Trevaskis, N. L., et al. Nat.

  46. Slide 46: Glyph Technology Platform: Exploring therapeutic approaches via the lymphatic system

    Glyph Technology Platform: Exploring therapeutic approaches enabled by trafficking via the lymphatic system Lipid prodrugs provide multiple opportunities to enhance small molecule drug distribution A Immuno-oncology Immunomodulation A Transport to mesenteric lymph nodes Metabolic/ GI-Lymphatic Neuro

  47. Slide 47: Appendix B: Founded Entities

    Appendix B: Founded Entities 47

  48. Slide 48: Karuna: Selectively activating muscarinic acetylcholine receptors in the brain

    Karuna: Selectively activating muscarinic acetylcholine receptors in the brain PRTC Ownership: 12.8%* KarXT  KarXT is a selective muscarinic receptor agonist for the treatment of psychosis and cognitive impairment across CNS disorders Muscarinic Xanomeline Key Highlights agonist CNS active agonist

  49. Slide 49: KarXT Phase 2 primary endpoint: PANSS Total Score at week 5

    KarXT Phase 2 primary endpoint: PANSS Total Score at week 5, and topline results  Clinically meaningful and statistically significant improvement in total PANSS vs. placebo, with 11.6 point improvement at Week 5 with p<0.0001  Statistical separation at every assessed time point  Statistically sig

  50. Slide 50: Karuna pipeline and upcoming milestones

    Karuna pipeline and upcoming milestones Discovery/ Upcoming Product candidate Indication Phase 1 Phase 2 Phase 3 Preclinical Milestone Phase 3 study #1 (EMERGENT-2) Schizophrenia initiation by end of 2020 KarXT Phase 1b topline Dementia-related psychosis data end of 2020 IND-enabling Other Muscarini

  51. Slide 51: Gelesis: FDA-cleared for the broadest patient population of any weight management aid

    Gelesis: FDA-cleared for the broadest patient population of any weight management aid PRTC Ownership: 21.0%* Plenity®1, GS100, GS200, GS300, GS500 ~150M  Proprietary mechanically-acting Individuals in the US with overweight and hydrogel platform, made from naturally- obesity within Plenity’s label

  52. Slide 52: Consumer expectations for weight loss provide an opportunity for Plenity

    Consumer expectations for weight loss provide an opportunity for Plenity® in target population of BMI <35 US Population Plenity’s Target 50M 47M Current Rx options have safety 33M and tolerability challenges 23M 19M So, they are reserved for highest risk high BMI patients (60% of use in BMI 25-27 BM

  53. Slide 53: Key findings from Plenity pivotal study

    Key findings from Plenity® pivotal study RESPONDERS SUPER RESPONDERS ADULTS ACHIEVING 5% OR GREATER WEIGHT LOSS ADULTS ACHIEVING 10% OR GREATER WEIGHT LOSS 26% • 26% of adults with overweight or obesity were super-responders to Plenity, losing on average 14% of their weight (30 pounds) 6 out of 10 C

  54. Slide 54: Plenity go-to-market approach

    Plenity go-to-market approach 1 Patients drive demand of Directly tap consumer demand via targeted digital engagement and influencer focus 2 Lower barrier to access by both driving Strong base of telehealth and traditional physician visits physicians ready to while leveraging mail order to create an

  55. Slide 55: Gelesis pipeline and upcoming milestones

    Gelesis pipeline and upcoming milestones: Mechanical properties regenerating gut barrier and other mechanisms have led to compelling preclinical and clinical data in additional indications (e.g., NASH/NAFLD and CIC) Discovery/ FDA Upcoming Product candidate Indication Phase 1 Phase 2 Phase 3 Preclin

  56. Slide 56: Follica: Growing new hair based on innovative findings in regenerative biology

    Follica: Growing new hair based on innovative findings in regenerative biology PRTC Ownership: 78.3%* Follica Platform Currently-approved treatments work with • Proprietary in-office treatment combines targeted ~90M only the hair you already have, either transplanting existing hair, or reviving scal

  57. Slide 57: Sample patient outcome from FOL-004 data

    Sample patient outcome from FOL-004 data  Follica is developing an approximately five-minute in-office experimental procedure associated with limited downtime Screening Day 85  Follica’s approach is comprised of a proprietary device designed to stimulate hair follicle growth, followed by treatment

  58. Slide 58: Akili: First game-based digital therapeutic cleared by the FDA for ADHD

    Akili: First game-based digital therapeutic cleared by the FDA for ADHD PRTC Ownership: 34.0%* EndeavorRxTM (AKL-T01), AKL-T02, AKL-T03, AKL-T04  Personalized digital therapeutics engineered to directly improve cognitive and attention impairments  Delivered through immersive action video game expe

  59. Slide 59: Achieved primary endpoint in pivotal study for pediatric ADHD

    Achieved primary endpoint in pivotal study for pediatric ADHD Tests of Variables of Attention (T.O.V.A.), FDA-cleared ADHD treatment monitor  Achieved primary endpoint in randomized, controlled pivotal study for AKL-T01 in pediatric ADHD in Q4 2017  AKL-T01 showed statistically significant change

  60. Slide 60: Akili pipeline

    Akili pipeline Discovery/ Phase 1 Phase 2 Phase 3 FDA Product candidate Indication Preclinical (Feasibility) (POC) (Pivotal) Clearance EndeavorRxTM Cleared by FDA Pediatric ADHD1 (AKL-T01) European CE Mark Granted Behavioral AKL-T02 Pediatric autism2 AKL-T03 Major depressive disorder3 Mood & affecti

  61. Slide 61: Vedanta: Developing a new class of drugs to modulate the human microbiome

    Vedanta: Developing a new class of drugs to modulate the human microbiome PRTC Ownership: 50.4%* VE303, VE202, VE416, VE800 100 – 120K CDI is typically treated using antibiotics  Defined consortia to shift microbiota, stimulate high-risk CDI cases per year which damage the microbiome, leaving immun

  62. Slide 62: Vedanta pipeline and upcoming milestones

    Vedanta pipeline and upcoming milestones Discovery/ Upcoming Product candidate Indication Phase 1 Phase 2 Phase 3 Preclinical Milestone Phase 2 data VE303 High-risk C. difficile (CDI) readout 2020 Phase 1/2 data VE416 Food allergy readout 2021 Phase 2 initiation VE202 Inflammatory bowel disease 2021

  63. Slide 63: Vor: Selectively protecting healthy cells from targeted cancer therapies

    Vor: Selectively protecting healthy cells from targeted cancer therapies PRTC Ownership: 11.8%* eHSC Platform >20K/year  Engineered hematopoietic stem cells (eHSCs) deleting redundant epitopes, protecting healthy Acute myeloid leukemia patients diagnosed in the US cells from targeted therapies The

  64. Slide 64: Alivio: Locally-acting therapeutic for devastating GI disease

    Alivio: Locally-acting therapeutic for devastating GI disease PRTC Ownership: 78.6% ALV-306, ALV-304, ALV-107  Novel technology designed to selectively bind to inflamed tissues and allow for targeted treatment of inflammatory disorders Current drugs for GI autoimmune Key Highlights 70 – 135K condit

  65. Slide 65: Sonde: Voice-based technology to transform how we monitor health

    Sonde: Voice-based technology with the potential to transform how we monitor health PRTC Ownership: 45.8%* Sonde ~17M  Developing proprietary technology to enable effective disease screening and management solutions based Individuals in the US are affected by depression on an analysis of seconds of

  66. Slide 66: Appendix C: Supplemental Materials

    Appendix C: Supplemental Materials 66

  67. Slide 67: PureTech is executing and delivering results

    PureTech is executing and delivering results Regulatory Partnerships FDA Clearance & EndeavorRx™ (AKL-T01)  Akili’s partnership with Shionogi Up to $20M in upfront payments with the potential to receive milestone payments for Japan and Taiwan commercialization of up to an additional $105M in additi

  68. Slide 68: Product Candidate Details (1 of 3)

    Product Candidate Details (1 of 3) Product PureTech Indication Potential Key Differentiation Results & Milestones Expected Milestones Candidate* Ownership** (US Patient Population) LYT-100 100% (Internal) Lymphatic flow disorders, incl. Product candidate for the potential treatment • Acquired LYT-10

  69. Slide 69: Product Candidate Details (2 of 3)

    Product Candidate Details (2 of 3) Product PureTech Indication Potential Key Differentiation Results & Milestones Expected Milestones Candidate* Ownership** (US Patient Population) VE303 50.4% High-risk CDI (100 – 120K per year) Developing a new category for immune- • Announced successful Phase 1a/1

  70. Slide 70: Product Candidate Details (3 of 3)

    Product Candidate Details (3 of 3) Product PureTech Indication Potential Key Differentiation Results & Milestones Expected Milestones Candidate* Ownership** (US Patient Population) Plenity® 21.0% Overweight and obesity (~150M) Only prescription weight management product • Plenity® received FDA clear

  71. Slide 71: PureTech: Key highlights

    PureTech: Key highlights 1 Seasoned team with track record of outperforming 2 Substantial existing value and near-term upside 3 Founded Entities contain significant value & growth potential 4 Wholly Owned Pipeline with multiple near-term catalysts 5 Successful business model poised for accelerated g

PureTech Health — Investor Presentation (September 2020) on 6ix